NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

NCT05262673 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

B-Cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: Antigen-specific T cells CART/CTL and DCvac

Sponsor

Shenzhen Geno-Immune Medical Institute